NCT01909830已完成2 期
A Phase II Study to Evaluate Activity and Toxicity of Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2012年7月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
Study Design:
Multicenter, non randomized, open label phase II study designed to evaluate the efficacy and safety of Gemcitabine/Pemetrexed combination.
Enrollment period: 18 months. Treatment period: maximum for 24 weeks for each patient (12 cycles lasting 2 weeks).
Total duration of the study: 24 months.
Number of Subjects:
Approximately 38 subjects will be enrolled on study:
- First stage:12 patients enrolled
If 1 or 0 responses were observed, the trial had to be terminated:
- Second stage: an additional of 23 patients were to be enrolled. If 5 or less responses were observed in 35 patients, the combination would not be considered worthy of further study, while if 6 or more responses were observed, the combination would be considered sufficiently active to warrant further testing. Taking into account an invalidity rate of 5%, 38 patients will be needed for this step.
详细描述
A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer Patients
Study Design:
Multicenter, non randomized, open label phase II study designed to evaluate the efficacy and safety of Gemcitabine/Pemetrexed combination.
Study Duration
Enrollment period: 18 months. Treatment period: maximum for 24 weeks for each patient (12 cycles lasting 2 weeks).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic confirmed diagnosis of colorectal carcinoma with metastatic (STAGE IV) disease.
- •Measurable disease according to RECIST criteria
- •Prior chemotherapy for metastatic disease is required; prior regimens (in adjuvant oral advanced stage setting) must include 5fluorouracile, Oxaliplatin and Irinotecan if not contraindicated.
- •At least a 4-week interval between the last dose of chemotherapy and study registration.
- •Recovery from all prior treatment-related toxicities to CTC <= grade 1 (except alopecia)
- •Male or female, aged >= 18 years
- •Life expectancy of greater than 12 weeks.
- •ECOG performance status <= 2
- •Patients must have normal organ and marrow function as defined below:
- •leukocytes >=3,000/microL
- •absolute neutrophil count >=1,500/microL
- •hemoglobin >= 9 g/dl
- •platelets >=100,000/microL
- •serum total bilirubin <= 1.5 X institutional upper limit of normal
- •AST(SGOT)/ALT(SGPT) <= 2.5 X institutional upper limit of normal (<= 5 times the upper institutional limits of normal if hepatic metastases are present)
- •serum creatinine <= 1.5 times the institutional upper limits of normal
- •Creatinine Clearance > 45 ml/min
- •The effects of Gemcitabine and Pemetrexed on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because therapeutic agents used in this trial are known to be teratogenic, female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception (hormonal or barrier method of birth control; abstinence) during the study and for 3 months thereafter. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •Participant is willing and able to give informed consent for participation in the study. Voluntary signed and dated written informed consent form in accordance with regulatory and institutional guidelines obtained before the performance of any protocol-related procedures not part of normal patient care.
排除标准
- •Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- •Participation in another clinical trial with any investigational agents within 30 days prior to study screening.
- •Previous treatment with Gemcitabine or Pemetrexed.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to Gemcitabine and/or Pemetrexed or other agents used in the study
- •Patients with active brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- •Past or current history of neoplasm other than colorectal carcinoma with a disease-free interval of less than 5 years, except for non-melanoma skin cancer or curatively treated carcinoma in situ of the cervix.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents 2 days before, the day of, and 2 days after the dose of pemetrexed single agent or pemetrexed plus carboplatin.
- •HIV-positivity, whether or not symptomatic.
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: 2 years
Determination of the objective response rate (ORR: CR (complete response) +PR (partial response) +SD (stable disease)) of treated patients according to RECIST criteria
次要结局
- Overall Survival (OS)(2 years)
- safety profile of study treatment(2 years)
- Time to Progression (TTP)(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid TumorDesmoid TumorNCT03802084Hyo Song Kim24
终止
2 期
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).Warm Autoimmune Hemolytic AnemiaNCT04253236Immunovant Sciences GmbH5
终止
1 期
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT03760666Clear Creek Bio, Inc.17
已完成
2 期
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor TherapyChronic Lymphocytic LeukemiaNCT02141282AbbVie127
已完成
2 期
Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian CancerOvarian CancerNCT04089189Impact Therapeutics, Inc.93